^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Breast Cancer
    Drug:Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)

    Excerpt:
    ...Progression-free Survival (PFS)`Overall Survival (OS)`Duration of Response (DOR)`Clinical Benefit Rate (CBR)`ORR in the Programmed Death Receptor-Ligand 1 (PD-L1) Positive Set`PFS in the PD-L1 Positive Set`OS in the PD-L1 Positive Set`DOR in the PD-L1 Positive Set...
    Trial ID:
    ENHANCE-1
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

    Excerpt:
    ...Number of participants with Adverse Events`the correlation between the expression of PD-L1 of circulating tumor cells and prognosis...
    Trial ID:
    NCT05402722
    Less C2 evidence
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome

    Published date:
    12/11/2020
    Excerpt:
    The detection of single PD-L1+mCTCs after eribulin treatment was correlated with shorter PFS (p = 0.047) and OS (p = 0.020). In conclusion, our study identified for the first time that cluster and single PD-L1+mCTCs subpopulations are of clinical significance in patients with MBC and highlighted the importance of CTC phenotyping during treatment with eribulin.
    DOI:
    10.3390/cancers12123735